Placebo Controlled Trial of NRX-101 for the Maintenance of Stabilization From Acute Suicidal Ideation and Behavior in Bipolar Depression (STABIL-B)
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Cycloserine/lurasidone (Primary)
- Indications Bipolar depression; Suicidal ideation
- Focus Registrational; Therapeutic Use
- Sponsors NeuroRX
- 23 Mar 2017 Planned initiation date changed from 1 Jan 2017 to 15 Jun 2017.
- 04 Jan 2017 According to a NeuroRx media release, company is now enrolling study sites for its clinical trial of NRX-101.
- 04 Jan 2017 According to a NeuroRx media release, company has received FDA clearance to proceed with this trial under an IND application.